glp-1 pots Dr. Blitshteyn and her research ream reported a patient with who improved on semaglutide (Ozempic). 🧠 While many patients with POTS, dysautonomia and Long COVID feel better on RAs Users have emphasized realistic expectations Why Your POTS Got Worse

10.1016/j.isci.2020.101097 265 ParakhS.SpencerD

Historical vignette: hypophosphatasia: molecular diagnosis of Rathbuns original case

By binding to GLP-1 receptors in the hypothalamus, they reduce appetite and promote satiety, leading to significant weight reduction in clinical trialswith newer agents achieving approximately 15% weight loss in obesity without diabetes (semaglutide) and up to 21% (tirzepatide), with somewhat lower reductions typically seen in patients with type 2 diabetes

Glass vials do not fully block UV light, and prolonged exposure to bright light can contribute to peptide degradation over weeks